MyJournals.org - Science - Single-trial extraction of event-related potentials (ERPs) and classification of visual stimuli by ensemble use of discrete wavelet transform with Huffman coding and machine learning techniques (Journal of NeuroEngineering and Rehabilitation)
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
– Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial –
– Conference Call and Webcast Today, December 17, 2020 at 8:30 am ET –
DEVON, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided an update on its meeting with the U.S. Food and Drug Administration (FDA) regarding its Fragile X syndrome (FXS) program. The Company plans to conduct a double-blind, placebo-controlled pivotal trial in patients with FXS who have a highly methylated